ReviewAdvances in experimental medicine and biology2025
MFRP in Early Onset Retinal Degeneration: Clinical and Molecular Perspectives.
Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characterization of Ocular Developmental Disorders in the Israeli Population: Genotype-Phenotype Correlations and Novel Candidate Genes.Biomolecules · 2026Article
- Retinal pigment epithelium pathology in age-related macular degeneration: mitigation with melatonin.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The membrane-frizzled related protein (MFRP) is a retinal pigment epithelium (RPE) and ciliary epithelium-expressed gene of unknown function. Interest in MFRP stems from clinical manifestations that range from acute-angle closure glaucoma to microphthalmia and Retinitis pigmentosa in patients with MFRP mutations. Furthermore, the genetic ablation of Mfrp in mice results in an early-onset retinal disease with visible degeneration around 1mo of age and primary rod photoreceptor loss. Yet, little is known regarding the exact role of MFRP in the RPE, its underlying contribution to pathology, and the impacted mechanisms at the early stages of MFRP-related disease. This review presents a current overview of MFRP studies and poses outstanding questions that are crucial for understanding the involvement of MFRP in early-onset retinal degeneration. Such insight could pave the way for deciphering the molecular mechanisms associated with MFRP that are impacted during early stages in the retina, offering the potential to translate this knowledge into determining similarities and differences in mechanisms involved in late-stage retinal diseases.
Indexed as
Identifiers
39930176What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.